Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: JCO Precis Oncol. 2020 Apr 30;4:442–465. doi: 10.1200/PO.19.00345

FIG 6.

FIG 6.

Sensitivity and specificity to classify BRCA1/2 biallelic alterations v wild type were evaluated for different genome-wide loss of heterozygosity (gLOH) cutoffs. Sensitivity was defined as percentage of biallelic BRCA1/2 cases that were of high gLOH (gLOH-high). Specificity was defined as percentage of BRCA1/2 wild-type cases that were negative for the gLOH-high biomarker. A cutoff that maximized the combined sensitivity and specificity score was identified (dotted black line; see Data Supplement). CUP, cancer of unknown primary; NSCLC, non–small-cell lung cancer.